StemCell Therapy

TRUMBULL, Conn., Dec. 15, 2020 /PRNewswire/ --ZetrOZ Systems, developers of the Sustained Acoustic Medicine (SAM) wearable ultrasound, an FDA-cleared bio regenerative medical device, was recently evaluated in a research study published in the Global Journal of Orthopedics Research, which measured the effectiveness of SAM treatment to reduce pain and improve function in athletes in conjunction with traditional therapies following sports-related musculoskeletal injuries. According to the study, the data "confirms the effectiveness of the application of SAM ultrasound in reducing pain as adjunct therapy or standalone therapy."

"The study confirms the effectiveness and benefits for home users, both athletes and non-athletes, who have sustained some kind of musculoskeletal injury," according to Dr. George Lewis, Founder and CEO of ZetrOZ. "The cases referenced in the study indicate SAM's ability to penetrate deep into muscle tissue and provide relief from pain and injury with regular treatment, helping accelerate the healing process and decrease the time it takes to recover."

The study included a case series of 18 professional and collegiate athletes who suffered a musculoskeletal, sports-related injury. The athletes were treated with SAM as supplementary therapy at a specified sports medicine rehabilitation clinic. Regular treatments resulted in 'reduced pain and improved function across numerous muscles, ligament, and tendon conditions.' Most of the athletes in the study were able to return to normal activity, including sports, during their treatment period.

The athletes in the study had previously undergone surgeries or were being considered for surgery. By utilizing sustained acoustic medicine as a long-duration continuous ultrasound therapy, users can accelerate the natural process of healing by inhibiting inflammation, increase the rate of tissue regeneration, angiogenesis, and nutrient exchange.

To read the study in full, visit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544191/.

To learn more about ZetrOZ Systems and the company's SAM line of products, visitsamrecover.com.

About ZetrOZ Systems

ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut. The organization also has manufacturing facilities across the United States. ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis. Learn more atzetroz.comandsamrecover.com.

Media Contact

LedoraBrown

[emailprotected]

Related Images

real-world-outcomes-study-on-sam.jpg Real-world outcomes study on SAM wearable ultrasound treatment published in the Global Journal of Orthopedic Research 2020

SOURCE ZetrOZ Systems

See more here:
New Research Study Shows Efficacy of Sustained Acoustic Medicine as Add-on Therapy in Treating Sport-Related Injuries and Returning Athletes to Play -...

HELSINKI, Dec. 17, 2020 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug development company, today announced that they have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis' CDNF and xCDNF therapies (Parkinson's disease) using Nanoform's proprietary biological nanoparticle technology.

The planned and non-exclusive collaboration is intended to assess the utility of Nanoform's latest platform technology for biologic drugs. The technology was recently launched, post filing of a provisional patent application with the US Patent Office, to enable production of biological nanoparticles as small as 50 nm.

Subject to finalizing definitive agreements, Nanoform will in this partnership carry out, for compensation on standard commercial terms, two Proof of Concept studies on Herantis' CDNF and xCDNF molecules leveraging Nanoform's novel platform and its in-house formulation expertise. The goal of the planned collaboration is to increase the probability of success for enhanced BBB (Blood-Brain-Barrier) penetration in the nasal drug delivery route for CDNF and x-CDNF.

Nanoform is committed to supporting Herantis in the development of these programs and has undertaken to invest, subject to certain customary conditions, 1,600,000 euros in a planned immediate directed share issue by Herantis.

"We are delighted to support Herantis Pharma in their development programs in CDNF and latest generation xCDNF molecules. Completing this deal validates the strong market interest in, and potential value that, Nanoform's platform technologies can add to pharmaceutical development programs and to the patient" said Prof. Edward Hggstrm, CEO of Nanoform.

"We look forward to working together to enhance and enable superior formulations of the pioneering new drugs we have developed. Nanoform's technologies show much promise for enhanced drug delivery applications in this complex and challenging field. It is our hope that this will open up new possibilities for improving the lives of patients with Parkinson's and other related diseases. We value the opportunity to enter into collaboration with Nanoform and look forward to what the future brings." said Dr. Craig Cook, CEO, Herantis Pharma.

For further information, please contact:

Prof. Edward Hggstrm, CEO

[emailprotected]/ +358 29 415 0684

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

[emailprotected]/ +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

For more information please visit http://www.nanoform.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson's disease and other neurodegenerative diseases, and ii. Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. The Herantis programs are potentially disease modifying that treat the cause as well as symptoms of disease, and bring the innovation necessary to provide further treatment options in underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit https://www.herantis.com

Forward-Looking Statements (Nanoform)

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform's prospectus published (on May 22, 2020) in connection with Nanoform's initial public offering (the "Prospectus") under "Risk Factors" and in our other filings or documents furnished to the Finnish Financial Supervisory Authority in connection with the Prospectus. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nanoform/r/nanoform-and-herantis-partner-to-look-for-opportunities-to-enhance-bbb-penetration-of-cdnf-and-xcdnf,c3257538

The following files are available for download:

SOURCE Nanoform

Read the original post:
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules - PRNewswire

Ashok Shetty is a professor in the Department of Molecular and Cellular Medicine and associate director for the Institute for Regenerative Medicine at the Texas A&M University College of Medicine.

Texas A&M Health Science Center

Thousands of American troops who were deployed in theFirst Gulf War were exposed to a variety of chemicals that resulted in psychological and physiological symptoms that health experts call Gulf War illness (GWI), previously called Gulf War syndrome.

Ashok Shetty, professor in the Department of Molecular and Cellular Medicineand associate director for the Institute for Regenerative Medicine at theTexas A&M University College of Medicine, has teamed up withKimberly Sullivan from the Boston University School of Public Health and Dr. Nancy Klimas Nova Southeastern University to investigate the extent and mechanisms of brain inflammation in veterans with GWI through a liquid biopsy approach. Their research efforts are being funded by a $1 million grant from the Department of Defense(DOD) over a three-year period.

The condition is characterized by a collection of unexplained chronic symptoms that can include gastrointestinal problems and dermatitis(a skin disorder) or central nervous system problems such ascognitive dysfunction, neuroinflammation, memory problems and depression.Nearly 30% of Gulf War veterans suffer from chronic GWI.Currently, the mechanisms underlying these persistent issues are unknown.

Shettysearlier studies on GWIfocused on theanimal model of GWI, recreating the conditions and chemicals veterans were exposed to during the war. He found that the animal models developed cognitive problems and had increased behavior that was associated with inflammation in the brain. His studies showed that the neuroinflammation in the brains of the animal models was progressive and had gotten worse over time, which explains why GWI is still prevalent in Gulf War veterans 30 years after the war.

Compared to an animal model approach, studying the brain in veterans with GWI is difficult. Therefore, most research with humans has been done through blood sampling, but its difficult to see if the results actually reflected what was happening in the brain. As a result, Shetty developed a liquid biopsy approach, which involves the characterization of the composition of brain-derived extracellular vesicles in the blood.

Shetty and his team will use this liquid biopsy approach to study neuroinflammation in the blood of Gulf War veterans beginning in early 2021.

The Sullivan and Klimas laboratories will collect blood samples of 50 veterans with GWI (patients) and 50 veterans without GWI (controls). Once the blood samples are collected, they will send the samples to Shettys laboratory. Shetty will then use the blood samples to isolate the extracellular vesicles (EV) membrane-enclosed nanosized vesicles that carry cargo such as proteins, lipids and micro-RNAs that come from the brain.

Once the extracellular vesicles are isolated, he will classify each one as a neuron-derived extracellular vesicle (NDEVs) or an astrocyte-derived extracellular vesicle (ADEVs) using a specific tagging technology. Then, Shetty will examine the cargo in the NDEVs and ADEVs, particularlyproinflammatory mediatorsand microRNAs using biochemical assays and RNA sequencing.

Because the composition of EVs reflects the physiological or pathological state of cells from which they are derived at the time of secretion, analysis of EVs derived from specific brain cells in the blood would help in the identification of biomarkers linked to chronic brain impairments, Shetty said.

What this approach means is by just looking at the vesicles, one can tell what is going on in the brain, even the brain cannot be directly studies. This technique of isolating extracellular vesicles was developed by Shetty in 2019, when he used an animal model approach.

Whatever is happening in the brain can be determined by characterizing brain-derived vesicles in the blood, Shetty said. It can be neuron-derived vesicles and astrocyte-derived vesicles, so this project is about that. But now, instead of animal models, we are studying actual veterans. From this human study, we can identify the extent of neuroinflammation in veterans.

Ultimately, this study will likely provide evidence as to why GWI is worse for some veterans compared to others, help diagnose the extent of brain inflammation in veterans with GWI and help determine whether GWI puts veterans at a higher risk for developing other neurological diseases.

The approach is also efficient in future clinical trials for monitoring the remission or progression of brain inflammation with apt treatment strategies, Shetty said.

Read more here:
Texas A&M Professor Awarded Department Of Defense Grant For Gulf War Illness Research - Texas A&M University Today

-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide-

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV.

While we have demonstrated the promise of CRISPR/Cas9 gene editing ex vivo in sickle cell disease and beta thalassemia, an in vivo approach to editing hematopoietic stem cells could allow the transformative benefit of CRISPR/Cas9 to reach a broader array of patients, including those in low resource settings that lack sufficient infrastructure for stem cell transplantation, said Tony Ho, M.D., Executive Vice President and Head of Research & Development at CRISPR Therapeutics. We look forward to working on new therapies that could contribute to the global effort to reduce the burden of HIV.

The grant builds upon CRISPR Therapeutics proprietary CRISPR/Cas9 gene editing technology and expertise in editing hematopoietic stem cells and contributes to efforts to accelerate transformative medicines for global health.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking StatementThis press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Ho in this press release, as well as regarding CRISPR Therapeutics expectations about any or all of the following: (i) the expected benefits of CRISPR Therapeutics research funded by the Bill & Melinda Gates Foundation and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be favorable and predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; potential impacts due to the coronavirus pandemic, such as the timing and progress of preclinical studies; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com

See the original post here:
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - GlobeNewswire

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies 2020" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent innovations in digital health, microbiome, and flu vaccines technologies. The TOE also provides insights across latest advancements for chronic pain management and COVID-19 testing.

The TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/v6l8dq

See the article here:
Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies, 2020 Report - Focus on Latest Advancements for Chronic Pain...

New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts, 2020-2030" - https://www.reportlinker.com/p05995354/?utm_source=GNW However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

SCOPE OF THE REPORTThe 3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030 report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:Brigitte Angres (Co-founder, Cellendes)Bill Anderson (President and CEO, Synthecon)Anonymous (President and CEO, Anonymous)Anonymous (Co-founder and Vice President, Anonymous)Scott Brush (Vice President, BRTI Life Sciences)Malcolm Wilkinson (Managing Director, Kirkstall)Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)Tanya Yankelevich (Director, Xylyx Bio)Jens Kelm (Chief Scientific Officer, InSphero)Walter Tinganelli (Group Leader, GSI)Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information includeAnnual reportsInvestor presentationsSEC filingsIndustry databasesNews releases from company websitesGovernment policy documentsIndustry analysts views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWEREDWho are the leading industry players engaged in the development of 3D cell culture products?What are the most popular 3D cell culture products?What are the different applications for which 3D cell culture products are currently being developed?What are the key factors that are likely to influence the evolution of this market?What is the trend of capital investments in the 3D cell culture systems market?Which partnership models are commonly adopted by stakeholders in this industry?How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?How is the current and future opportunity likely to be distributed across key market segments?What are the anticipated future trends related to 3D cell culture systems market?

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term.Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions)Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p05995354/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,...

Pune, India, Dec. 14, 2020 (GLOBE NEWSWIRE) -- The report mentions that the Gene Therapy Market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period. The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help in treating cancer in those patients who are at high risks of getting affected by this disease through genetic mutations. In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions.

KEY INDUSTRY DEVELOPMENTS:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/gene-therapy-market-100243

Increasing Innovations & Research Activities to Boost Growth

The U.S Food and Drug Administration (FDA) stated that it is expecting to receive more than 200 applications of this therapy by the end of 2020. This showcases that the rising number of research studies and innovations in this field would affect the gene therapy market growth positively in the near future. In North America, almost 208 companies are currently operating in this market. In addition to this, the Alliance for Regenerative Medicine declared that as of 2018, approximately 259 potential drug candidates are under Phase I clinical trials across the globe.

However, the outbreak of the COVID-19 pandemic is presently impacting the field of research. According to the director of the Office of Tissues and Advanced Therapy (FDA) named Wilson Brayan, nowadays the officials are prioritizing only those drugs that are associated with coronavirus.

To get to know more about the short-term & long-term impact of COVID-19 on this market, please click here: https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243

The U.S. to Dominate Owing to Presence of Favorable Policies

In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions.

Besides, the presence of favorable reimbursement policies and guidelines would also help in propelling the market growth here. As this type of treatment is not legal in several developing nations, industry giants are emphasizing on the U.S. for launching their products.

Europe, on the other hand, is anticipated to grow significantly backed by the adoption of unique treatment options. Asia Pacific is set to hold a comparatively lower share on account of the decreasing usage of gene therapy because of its expensive nature.

Quick Buy - Gene Therapy Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100243

List of Key Players operating in Gene Therapy Market:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/gene-therapy-market-100243

Global Gene Therapy Market Segmentations:

By Application

Oncology

Neurology

Others

By Vector Type

Viral

Non-viral

By Distribution Channel

Hospitals

Clinics

Others

By Geography

U.S.

Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)

Asia-Pacific (Japan, China, and Rest of Asia- Pacific)

Rest of World

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/gene-therapy-market-100243

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Have a Look at Related Reports:

India Peritoneal Dialysis Market Share & Industry Analysis, By Type (Continuous Ambulatory Peritoneal Dialysis (CAPD), Automated Peritoneal Dialysis (APD)), By Product (Devices (Cyclers/Machines), PD Solutions/Fluids, PD Sets, Catheters) Forecast, 2019-2025

Guidewire Market Share & Industry Analysis, By Product (Coronary Guidewire, Peripheral Guidewire, Urology Guidewire, Neurovascular Guidewire, and Others) By Material (Nitinol, Stainless Steel, and Others) By Coating (Coated and Non-Coated) By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2019-2026

India Insulin Pumps Market Share & Industry Analysis, By Product (Insulin Pumps (Tethered Pumps and Patch Pumps) and Consumables (Reservoirs, Infusion Sets, and Others) and Region Forecast, 2019-2025

Lactose Market Share Trends & Industry Analysis, By Purity (Crude Lactose, Edible Lactose, and Refined-edible Grade Lactose), By Color (Yellow Lactose, Pale-yellow to White Lactose, and White Lactose), By Applications (Food, Feed, Infant Formula, and Pharmaceuticals), and Regional Forecast, 2019-2026

Contact Lenses Market Share & Industry Analysis, By Modality (Reusable and Disposable), By Design (Toric, Multi-focal, and Spherical), By Distribution Channel (Retail Stores, Online Stores, and Ophthalmlogists), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/global-gene-therapy-market-10136

Go here to see the original:
Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -...

I had REGENCare treatments in October, and I just again today, and theyre fantastic. They just help rejuvenate my entire system, help replenish the muscle tissue, help just heal any nagging injuries that are throughout my body. REGENCare treatments are fantastic and its an all-natural way to heal.

ATLANTA (PRWEB) December 14, 2020

Announcing the launch of REGENCare Life Magazine. Published in conjunction with Local Umbrellas C4 Lead Machine, the inaugural issue features interviews with Rob Gronkowski, the Atlanta Braves legendary Ryan Klesko and Atlantas Celebrity Anti-Aging Expert, Dr. Richard Ambrozic (@drrick), regarding the very latest in Regenerative Therapies designed to renew and restore function in the body. The magazines inaugural edition features stories and testimonials from professional athletes and many other patients benefiting from these Allograft Regenerative Therapies.

REGENCare Life Magazine features an interview with Tampa Bay Buccaneers tight end Rob Gronkowski by C. Christie Craig. (See Interview below.)

The highs and lows of football players are well known. When you are young, strong, and focused, the game has no limits. But the body can only take so many hits; there is a huge price to pay for years of playing hard on the field. Rob Gronk Gronkowski, one of the NFLs all-time greatest tight ends, knows this all too well. In 2019, Rob announced his retirement from the New England Patriots, needing a break to focus on his health and well-being. At 30 years old, he had an extraordinary run, making his mark in football history. Fans were devastated and Rob was hurting.

Today, after a multitude of various regenerative treatments throughout last year, Robs new nickname is Mr. Recovery. His body and mind are healed, and he has a fresh new deal with the Tampa Bay Buccaneers. The best part is hes going to share his most amazing discovery. In fact, he is ready to shout it out to all who will listen. Thats good news, because when it comes to overcoming pain, hes someone we should listen to carefully. Not only is he an amazing athlete; he is also a successful businessman and philanthropist.

Gronk was always well-loved by fans and teammates, and many thought his career was over. But he was not the type to give up, and he decided that pain was not going to mean the end of his story. How he eliminated it and got back on the field is an inspiring story for all of us. In this interview, Rob shares how he found his fire and returned to the NFL through regenerative care treatments. Here is the incredible story of his journey back to health and wellness in his own words.

Question: I am here with the greatest tight end in NFL history who now calls himself Mr. Recovery. After a litany of injuries, you are coming out of retirement this year and making your comeback with the Tampa Bay Buccaneers. How did this all happen?

Gronk: Thank you! I am super excited, super pumped up. I feel so good, you know. I let my body heal and recover. Ive been playing football for fifteen plus years, plus along with other sports, and with all this action Ive seen, my body just needed a little rest. I had to investigate and find connections to heal. Dr. Rick turned everything around for me. Its a full-time job as an athlete. Athletes dont just show up. We have to take care of our bodies and find solutions that work. The recovery is cake with Dr. Rick.

Question: Your journey back to health is unprecedented. Few NFL players return to action after retiring like you did. Allografts are the new buzz words for lasting recovery. Is this the type of therapy and injections you received from Dr. Rick at REGENCare?

Gronk: Yes, I had REGENCare treatments in October, and I just again today, and theyre fantastic. They just help rejuvenate my entire system, help replenish the muscle tissue, help just heal any nagging injuries that are throughout my body. REGENCare treatments are fantastic and its an all-natural way to heal. This treatment is exactly what I needed. I am sharing this information with others because this treatment isnt only for professional athletes like me. It can help everyone!

Question: How is your healing different with REGENCare Therapy compared to traditional treatment?

Gronk: In your early twenties you really dont get into the treatment. You just do the basics and the bare minimum. But as you get older, you have to treat your body more, you need to find new ways, and thats what Ive been doing over the last few years. Aside from the allografts, there are so many options at REGENCare. Im getting massages, doing vitamin IVs, and lying in the hyperbaric chamber. This chamber fills my body up with clean, pure oxygen. Without oxygen in your body, you are not going to survive! Its just spectacular when you can get more and more oxygen into your system. Your muscle tissues start feeling pliable and loose and it targets all those nagging injuries to help them heal. It is my favorite treatment because I get a nap and I am getting rejuvenated at the same time by all the oxygen. Its great. We also do a couple other treatments to help with recovery, stress management, improving sleep and diet.

Question: Do REGENCare Therapy treatments make a difference in how fast you recover and heal?

Gronk: I definitely feel a big difference. Back in the day, I would just let my body heal naturally, and when I say naturally, I would just do the bare minimum. I would be running around on it. I would be partying on the injury while it was trying to heal. But I was so young then, and I could get away with it. But now that I want to continue my career, and Im older, I learned that I needed to start adapting. You got to adapt to the change, you got to start adapting to your body. And you know, finding that adaptation includes a whole spectrum of healing treatments from allografts and finally, to proper nutrition.

Question: How does your focused mindset play a role in your healing? Is it an importantpart of your treatment process?

Gronk: Yeah, definitely! Some people can be telling you to do this, and you just got to stick with your gut. You got to stick with your heart, knowing what is best for your body. To know that, you have to go through a lot of experiences. Ive tried many, many things, and some do work for me. I focus on all the natural treatments that you could do for yourself. I find the best ones that suit me and enjoy em while doing em.

What would you tell your friends and teammates who are suffering from chronic pain and injuries about these regenerative treatments?

Gronk: Just get started on it now! The longer you wait, the harder it is going to be to heal that injury and nagging pain. The longer you wait, it gets more settled into your brain that you have that nagging pain. So hop on it ASAP, get moving, get cruising on it, find some good workouts, strengthen your core tight, and start small. Thats where it begins. You dont got to go big at all. Just start small and make little changes.

Question: So whats next for you? You have an exciting season with Tampa Bay, what are some of the things that youre doing to prepare?

Gronk: You know, Im just hanging out! Throwing footballs, doing football workouts, doing band workouts, doing some strength workouts, just doing it all at high speed. Its a lot of expectations for sure. Just have to go in and be a consistent player and youre just ready to go. Im just excited to get back out into the field and play some football and help out the team.

Question: If you were to leave a legacy behind, what would it be?

Gronk: Just working hard, being the best teammate that I can be and doing the best that I can to help out the team. Now that Dr. Rick has helped me to recover, I can achieve this and more.

Get your copy & learn more about how Allograft Regenerative Therapies can help you at https://www.REGENCare.life.

Regenerative Medicine Treatments at REGENCare

Our regenerative medicine treatments utilize regenerative medicine to encourage tissue healing throughout affected areas. REGENCare utilizes regenerative medicine allografts, Pulsed Electro-Magnetic Field technology to stimulate and exercise the cells and address cellular dysfunction and support overall wellness, Shockwave Therapy to promote regeneration and repair of the bones, tendons and other soft tissues, Georgias first PRISM Light Pod which uses specific wavelengths of light that pass through layers of skin and interact within the body to stimulate regrowth and repair, IV Hydration which provides the vitamins, minerals, and amino acids your body needs, Hyperbaric Oxygen Therapy which can significantly increase the concentration of circulating progenitor cells within the peripheral circulation system, and more. We may be able to help in orthopedic conditions, like osteoarthritis, meniscus and cartilage tears, tendinitis, joints and back pain, inflammation, hair restoration, skin rejuvenation and anti-aging treatments.

About Richard Ambrozic, MD, Founder and CEO, REGENCare:

Dr. Ambrozic (@drrick) earned his MD from the University of Alberta. He completed a residency in health prevention and family medicine at the University of British Columbia and has completed an anti-aging fellowship from the University of South Florida. The American College of Sports Medicine, American Academy of Anti-Aging Medicine, American Medical Association, Medical Association of Georgia, and the American Society for Laser Medicine and Surgery. He is a member of the Harvard Medical School Postgraduate Association. He is an expert in Allografts, Lasers, and Anti-Aging.

Dr. Ambrozic is the founder of REGENCare, with locations in Buckhead, Atlanta, Jupiter/Palm Beach Florida, and soon around the world. He treats professional athletes, celebrities, and patients from all walks of life interested in regenerative and anti-aging medicine. Healing the body naturally and safely, without pills and unnecessary surgery is most important. Dr. Ambrozic has traveled the world to bring the very latest and state-of-the-art regenerative medicine protocols, technology, and procedures to his clinics.

Please call our office to book your free consultation so Dr. Ambrozic and the REGENCare team can plot your course to better health.

Call 678-430-3039 or email at appointment@regencare.life.

Please visit our website at https://www.REGENCare.life

Please visit our Social Media:

https://www.instagram.com/drrick/https://www.facebook.com/richard.ambrozichttps://www.linkedin.com/in/dr-richard-ambrozic-70206124/

Contact:

REGENCareDr. Richard Ambrozic (@drrick)Office Phone: 678-430-3039 Email: appointment@regencare.lifeAddress: 240 Pharr Rd. Atlanta, GA 30305 (Buckhead Village)

Read the original post:
REGENCare Life Magazine Interviews NFL's 3X Super Bowl Champion, Rob Gronkowski, and Atlanta's Anti-Aging Expert, Dr. Richard Ambrozic, Regarding...

Arthritis is a disease with over 100 variations that affects350 million people around the globeincluding an alarming number of children. While these numbers may be discouraging, the cheering news is that natural remedies like borax, apple cider vinegar, turmeric, baking soda and blackstrap molasses are quite effective. Home treatments for arthritis can not only relieve pain but prompt the body to heal itself.

Natural remedies for arthritis address the pain, inflammation, stiffness, and limited range of motion. Supportive foods and supplements provide needed materials for the bodys own repair of joint degeneration.

There are many excellent natural remedies for arthritis and they can be tailored to individual needs. It may take a combination of remedies to bring full relief.

Borax is a compound that exists in deposits around the world. It is mined from the earth and used in a variety of commercial and home settings. Borax contains sodium, hydrogen, oxygen and boron. Boron is a mineral required by the body. Higher concentrations of boron are found in strong bones than in weak bones. Boron is needed by the body for proper calcium-magnesium balance, another factor in a healthy skeletal system. This video will provide more extensive information about using borax for arthritis.

Raw and organic apple cider vinegar provides trace nutrients to the body and helps the body to become more alkaline which reduces pain. 1-2 teaspoons of apple cider vinegar can be added to a glass of water. This tonic is consumed once or twice a day. Apple cider vinegar is a popular remedy for weight loss. Losing excess weight often reduces arthritis symptoms and risks.

When an imbalance in the bodys natural pH level is the primary causes of arthritis, baking soda is an effective treatment option. Baking soda helps neutralize the bodys acidic state and return the body to alkalinity. Baking soda also provides carbonates to the body. Baking soda is a popular natural remedy for gout, one form of very painful arthritis.

Blackstrap molasses is a densely packed food. It contains calcium, magnesium, iron potassium, zinc selenium, and B vitamins to name a few! Nutritional deficiencies are common causes of many diseases. Restoring necessary nutrients to the body can allow it to heal itself. 1 tablespoon of blackstrap molasses contains 200 mg of calcium, which is 20% of the RDA for calcium for adults 50 and under. Calcium is critical to bone health, and calcium from foods is more easily assimilated into the body. 1 tablespoon of blackstrap molasses contains 25% of the RDA of magnesium for adults. Magnesium is necessary for healthy bones and cartilage. Copper is needed by the body to form connective tissue. Blackstrap molasses is a source of copper. Take note of the nutritional content of individual brands of blackstrap molasses. The amounts of nutrients in molasses does vary from brand to brand.

Turmeric is an herbal anti-inflammatory and a wonderful natural pain remedy. It can be taken in capsule form or added to milk. Golden milk is a popular way to take turmeric and is quite palatable. Curcumin in turmeric is they key to turmeric'santi-inflammatory and pain reducing properties. Early studies about the use of curcumin for arthritis are encouraging.1

Turmeric has few side effects, especially when compared to over the counter ani-inflammatory medications.

A number of essential oils have anti-inflammatory properties. Frankincense and peppermint essential oils are each excellent topical treatments for arthritis pain.

Frankincense has a long history in herbal medicine as an anti-inflammatory. Peppermint essential oil has a cooling effect on the body. Using peppermint and frankincense together makes a pleasant smelling topical pain reliever.

While some people use either of these oils neat, (undiluted) it is generally recommended to use essential oils with a carrier oil. Coconut oil or castor oil are two great carrier oils for arthritis treatment as each one has its own healing properties.

Vitamin C is needed by the joints for the synthesis of collagen. Vitamin C is also a natural anti-inflammatory. Evidence suggests that vitamin C has analgesic properties for those with joint and other pain.2

Sodium ascorbate is the best form of vitamin C to take. It is easier on the stomach and less acidic than the ascorbic acid form.

Bone broth is gaining popularity as a remedy for many degenerative conditions, including arthritis. Perhaps it would be better to say that it is regaining popularity. Generations ago bone broth was a staple in homes and used on a regular basis. Bone broth is made by a low simmering of bones and cartilage for 12-48 hours. During this time the nutrients that make up the bones and joints are extracted. Bone broth is chock full of just the nutrients needed for bone and joint repair! It is not difficult to make bone broth at home. Alternately, gelatin, collagen or store bought bone broth can be used.

Extra pounds cause extra stress to the joints, which promotes pain and degeneration. For every pound that a body is overweight there is a four pound increase in pressure on the knee joints. Someone who carries around only a modest 15 pound excess is placing an extra 60 pounds of force on the knee joints. Additionally, excess fat cells can aggravate arthritis conditions due the the inflammatory chemicals that are produced in the fat cells.3

Losing weight can reduce pressure on joints and reduce the inflammatory response in the body. Losing weight is definitely worth the trouble to improve health on many fronts. Weight loss goes hand in hand with the next important arthritis remedy on this list.

Exercise helps strengthen the body, including the muscles and the bones. Stronger muscles mean there is less stress on and more support for the joints. Exercise also promotes effective circulation. Better circulation allows for the bodys repair mechanisms to take place at a faster rate. Swimming is a wonderful exercise for those with arthritis. Walking is pleasant and more easily available. If your doctor permits, small hand weights can be used to strengthen joints and muscles in the arms. (The legs will be getting the benefit of weight bearing exercise by virtue of carrying the body.)

Food is the primary vehicle for needed vitamins, minerals and other nutrients to enter the body. Making calories count with healthy and nutrient dense foods gives the body something to work with. Whether arthritis is caused by wear and tear, genetics, obesity, infection, autoimmune diseases, metabolic imbalances or nutritional deficiencies, quality nutrition will support healing or at least can help to slow down the progression of disease. Excessive amounts of sugar and processed foods fill up the body and keep it from getting needed nutrients. They also contribute to obesity, which aggravates arthritis. Supplements may still be necessary and helpful but they will never completely overcome damage done to a body that gets very little nutrition from food.

Some specific nutrients that arthritis suffers need and good sources of them are listed below:

Calcium - kale, milk, milk kefir, cheese, sardines, lentils, almonds

Magnesium - quinoa, black beans, brown rice, tofu, dark chocolate,avocados

Vitamin C - pineapple, strawberries, kiwi fruit, red peppers, papaya, broccoli

Vitamin D - fortified milk, cereal, salmon and tuna

Folate - chickpeas, lentils, broccoli, and spinach

In addition to quality foods, positive dietary changes include plenty of quality liquids. Even mild dehydration can contribute to pain. A well hydrated body feels better. Fluids keep toxins moving out of the body.

Keep coffee and sodas to a minimum. Both can cause the body to be more acidic, making pain worse and contributing to compromised health. Plenty of qualitywatershould be consumed daily. Avoid distilled water as it can leach important minerals from the body, especially the bones.

Herbal tea is a wonderful way to fulfill needs for fluid and nutrition.

Try this nettle infusion daily to boost the intake of nutrients to benefit overall health, including that of the bones.

Nettle Infusion

Bring water to a near boil. Place nettle leaf in a quart jar. Pour water into jar over the leaf. Allow the tea (an infusion is a strongly brewed tea) to steep without further heat for 12 hours. (Prepare before bed for use the next day.) Strain out the nettle leaf. Lightly sweeten with honey as desired. Consume 4 cups daily. This tea will keep for 24 hours in the refrigerator. Peppermint or spearmint leaf can be added for flavor.

Earth Clinic has had many success reports for many different manifestations of arthritis and joint pain including gout, rheumatoid arthritis, ankylosing spondylitis and degenerative disc disease.

Do you have a natural remedy for arthritis? Please send us some feedback!

Continue reading to learn how our readers have treated arthritis with natural remedies!

Arthritis, Art Solbrig RemedyBoraxOsteoarthritisTurmeric

Read more here:
Most Effective Natural Remedies for Arthritis

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- Physio Logic, a leading provider of integrated health services in New York City and surrounding areas, continues to demonstrate its commitment to excellence in the field of Regenerative Medicine and Stem Cell Therapy by entering into a collaboration with Regenexx, a worldwide network of specially trained physicians providing the world's most advanced, research-driven, regenerative medicine and stem cell therapy treatments. The partnership brings cutting-edge regenerative treatments to New York City residents suffering from sports injuries or degenerative diseases.

The Regenerative Medicine division of Physio Logic is led by Dr. Tanuj Palvia, MD, a specialist in regenerative medicine and interventional orthopedics focused on the treatment of musculoskeletal injuries and degenerative orthopedic conditions.

"Stem Cell Therapy is one of the most innovative treatments available today but, being so new, patients need to know they're receiving the best possible care. As a physician, I hold myself and my practice to the highest standards and, being aligned with Regenexx adds that extra assurance patients need to know they're in good hands. Whether it's a nagging sports injury or slow degeneration, you're going to get the highest quality of integrated care right here at Physio Logic," said Dr. Palvia.

Interventional Orthobiologics is a specialty that focuses on using your body's natural healing agents to treat orthopedic injuries with the goal of reducing pain and improving joint function. The variety of orthobiologics available to Regenexx physicians, such as bone marrow stem cells and platelet-rich plasma (PRP), allow them to create a treatment plan to best support your recovery. It can be used in the treatment of conditions such as arthritis and injury to ligaments, tendons, cartilage, or bone.

"Being selected to represent the Regenexx brand in New York City speaks to the quality of our facility, our providers, and the care we give our patients," said Dr. Rudy Gehrman, CEO & Founder of the Brooklyn based clinic. "Physio Logic is raising the standard of healthcare in New York and our partnership with Regenexx is an extension of the quality, integrative care we provide to every patient that walks through our door."

Regenexx physicians are required to have thousands of hours of experience performing precise, injection-based treatments using image guidance for a range of body parts and injuries. Their strict acceptance criteria means that Regenexx only chooses the most qualified physicians to join their network. Physio Logic's Interventional Pain Specialist, Dr. Tanuj Palvia, MD, is ranked among them.

To learn more about Physio Logic and Regenerative Medicine, go to https://physiologicnyc.com/regenerative-medicine/

About Physio LogicPhysio Logic brings together an expert team of open-minded medical doctors, physical therapists, chiropractors, acupuncturists, massage therapists, nutritionists, health coaches, biohackers, and Pilates instructors. Our unique collaborative approach, coupled with our ability to assess patients holistically, is used to create a custom care plan tailored to patients' needs. For more information on Physio Logic, visit https://physiologicnyc.com or call (718) 260-1000.

About RegenexxRegenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative protocols available as an alternative to many orthopedic surgeries. Regenexx has published roughly half of the research worldwide on the use of orthobiologics for treating orthopedic injuries, and our patented treatment lab-processing and treatment protocols allow us to achieve unmatched results. Our procedures use your body's natural healing agents including blood platelets and bone marrow concentrate to repair damaged bone, muscle, cartilage, tendons and ligaments. For more information on Regenexx, visit https://regenexx.com.

Media contact:Alan Sott[emailprotected](718) 260-1000

SOURCE Physio Logic

http://www.physiologicnyc.com

More here:
Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire

Salivary immunoglobulin A (IgA) anticitrullinated protein antibodies (ACPAs) have been detected in a small subset of patients with rheumatoid arthritis (RA), and they are associated with higher levels of disease activity, according to study results published in Arthritis Research & Therapy.

In the current study, researchers sought to characterize salivary and circulating IgA ACPAs relative to disease characteristics and risk factors in patients with RA.

Patients with established RA from the County of Dalana, Sweden, were included in the Secretory ACPA in RA (SARA) study, with enrollment from 2012 to 2013. Participants were randomly selected from among those with planned follow-up visits at the Rheumatology Clinic, Falun Hospital, Sweden. Healthy blood donors were enrolled as control participants. Participants were required to provide at least 0.5 mL of saliva during the 10-minute sampling time to be included in the study. Paired saliva and serum samples were collected from patients during their visit to the rheumatology clinic. All participants were requested to refrain from eating, drinking liquids other than water, brushing their teeth, or smoking 1 hour before saliva sampling.

Overall, a total of 196 patients with RA and 101 healthy blood donors were enrolled in the SARA study. Using enzyme-linked immunosorbent assays that targeted reactivity to a cyclic citrullinated peptide, paired saliva and serum samples from all participants were evaluated for ACPA of IgA isotype, as well as for subclasses IgA1 and IgA2. Cutoff levels for positive serum and saliva tests were set at the 99th percentile for blood donors.

Results of the study showed that IgA ACPA in saliva was detected in 12% of patients with RA; IgA1 and IgA2 were reported in 10% and 9% of patients with RA, respectively. On the other hand, IgA ACPA in serum was found in 45% of patients with RA, IgA1 in 44% of patients, and IgA2 in 39%. Levels of IgA ACPA in saliva samples correlated significantly with serum levels of IgA (r =.455; P <.001).

Further, at the time of sampling, the presence of salivary IgA ACPA was linked to higher erythrocyte sedimentation rate, 28-joint disease activity, tender joint count, and patient global assessment at the time the samples were obtained. However, none of the antibodies were associated with smoking, HLA/DRB1/shared epitope, or radiographic damage.

One of the study limitations was the fact that the radiographic outcome was based on written reports by radiologists and not formal scoring.

Researchers concluded, This [study] suggests that mucosal ACPA responses in the oral cavity may contribute to disease-promoting processes in RA.

Roos Ljungberg K, Brjesson E, Martinsson K, Wetter J, Kastbom A, Svrd A. Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):274. doi:10.1186/s13075-020-02363-0

Read the original:
Higher Disease Activity Associated With Salivary IgA ACPAs in Patients With RA - Rheumatology Advisor

Objectives:To explore the prognostic value of pre-specified comorbidities on treatment outcomes in PsA, and to compare baseline data with cutaneous psoriasis without arthritis and healthy controls (HC).

Methods:Patients initiating conventional synthetic/biological disease-modifying antirheumatic drugs were enrolled in this clinical observational cohort study, and data on comorbidities, and clinical and patient-reported outcomes were retrieved at baseline and after 4 months. Pearsons chi-squared tests were performed to investigate the prognostic value of pre-specified comorbidities and achievement of ACR20, DAPSA50 and MDA. Mann-Whitney U tests were used to compare OMERACT PsA Core Outcome Set (COS) measures at baseline and follow-up for the pre-specified comorbidities.

Results:A total of 100 PsA patients were included at baseline. Statistically significantly fewer patients with obesity achieved DAPSA50 compared with patients without obesity (P =0.035), and fewer patients with hypertension (P =0.034) and Charlson Comorbidity Index (CCI) 1 (P =0.027), respectively, achieved MDA compared with patients without these comorbidities. Patients with obesity, hypertension, widespread pain, and CCI 1 had significantly worse COS measures at follow-up compared with patients without these comorbidities. At baseline, patients with PsA had higher disease burden compared with patients with cutaneous psoriasis and HC, including higher pain (P <0.001) and fatigue (P <0.001) scores, and more widespread pain (P =0.002).

Conclusion:Obesity, hypertension and CCI 1 were prognostic factors for poorer treatment outcome rates in PsA. Pain and fatigue were more frequently reported among patients with PsA compared with patients with cutaneous psoriasis and HC.

Trial registration:The Danish National Committee on Health Research Ethics: H-15009080; Data Protection Agency: 2012-58-0004; ClinicalTrials.gov:NCT02572700.

Keywords:PsA; TNF inhibitor; comorbidities; fatigue; pain.

Read the original post:
Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study - DocWire News

Background:Chronic inflammation in rheumatoid arthritis (RA) can induce reduced muscle mass (myopenia) and ectopic fat deposition probably showing normal body mass index (BMI). We aimed to investigate their body composition (BC) characteristics and clinical significance.

Methods:BMI and BC were collected in consecutive RA patients and control subjects. Myopenia was defined by appendicular skeletal muscle mass index (ASMI) 7.0 kg/m2in men and 5.7 kg/m2in women. Overfat was defined by body fat percentage (BF%) as 25% for men and 35% for women.

Results:There were 620 RA patients (57.6% with normal BMI) and 2537 control subjects (62.5% with normal BMI) recruited. After 1:1 age and sex matching with control subjects, RA patients with normal BMI (n= 240) showed significantly higher prevalence of myopenia (43.3%versus22.1%) and overfat (19.2%versus7.1%) as well as myopenia overlapping overfat (17.1%versus3.3%). In all RA patients with normal BMI (n= 357), there were 18.2% patients with myopenia overlapping overfat who had the worst radiographic scores and highest rates of previous glucocorticoid treatment and hypertension. Compared with those without, normal BMI RA patients with previous glucocorticoid treatment (24.4%versus10.3%) or hypertension (27.8%versus13.6%) had a higher rate of myopenia overlapping overfat. Previous glucocorticoid treatment [odds ratio (OR) = 2.844, 95% confidence interval (CI) 1.441-5.614] and hypertension (OR = 2.452, 95% CI 1.283-4.685) were potential associated factors of myopenia overlapping overfat in RA patients with normal BMI.

Conclusion:Myopenia overlapping overfat is an important extra-articular manifestation which should not be ignored in RA patients with normal BMI, especially with glucocorticoid treatment and hypertension.

Keywords:body composition; body fat; body mass index; hypertension; rheumatoid arthritis; skeletal muscle.

The rest is here:
Neglected extra-articular manifestations in rheumatoid arthritis patients with normal body mass index: reduced skeletal muscle overlapping overfat -...

PHILADELPHIA, Dec. 17, 2020 /PRNewswire/ --Immunotherapies, such as checkpoint inhibitor drugs, have made worlds of difference for the treatment of cancer. Most clinicians and scientists understand these drugs act on what's known as the adaptive immune system, the T cells and B cells that respond to specific threats to the body.

New research from a team co-led by Penn Dental Medicine's George Hajishengallis suggests that the innate immune system, which responds more generally to bodily invaders, may be an important yet overlooked component of immunotherapy's success.

Their work, published in the journal Cell, found that "training" the innate immune system with -glucan, a compound derived from fungus, inspired the production of innate immune cells, specifically neutrophils, that were programmed to prevent or attack tumors in an animal model.

"The focus in immunotherapy is placed on adaptive immunity, like checkpoint inhibitors inhibit the interaction between cancer cells and T cells," says Hajishengallis. "The innate immune cells, or myeloid cells, have not been considered so important. Yet our work suggests the myeloid cells can play a critical role in regulating tumor behavior."

The current study builds on earlier work by Hajishengallis and a multi-institutional team of collaborators, which showed that trained immunity, elicited through exposure to the fungus-derived compound -glucan, could improve immune recovery after chemotherapy in a mouse model.

In that previous study, the researchers also showed that the "memory" of the innate immune system was held within the bone marrow, in hematopoietic stem cells that serve as precursors of myeloid cells, such as neutrophils, monocytes, and macrophages.

The team next wanted to get at the details of the mechanism by which this memory was encoded. "The fact that -glucan helps you fight tumors doesn't necessarily mean it was through trained immunity," says Hajishengallis.

To confirm that link, the researchers isolated neutrophils from mice that had received the innate immune training via exposure to -glucan and transferred them, along with cells that grow into melanoma tumors, to mice that had not received -glucan. Tumor growth was significantly dampened in animals that received cells from mice that had been trained.

-glucan is already in clinical trials for cancer immunotherapy, but the researchers say this finding suggests a novel mechanism of action with new treatment approaches.

"This is a breakthrough concept that can be therapeutically exploited for cancer immunotherapy in humans," Hajishengallis says, "specifically by transferring neutrophils from -glucan-trained donors to cancer patients who would be recipients."

Contact: Beth Adams, [emailprotected]

SOURCE Penn Dental Medicine

Home

View original post here:
Priming the Immune System to Fight Cancer - PRNewswire

Newswise Nine-year-old Grace Moss of Laredo, Texas, was facing a daunting prospect. A tumor that had invaded her jaw had been removed, but now the plastic surgeon wanted to remove her fibula - the smaller of the two bones in her lower leg - to use as a graft.

"When I got the news that the next surgery was going to be a graft of a bone from her leg, I started thinking, 'There has to be another option. Grace is just an active little girl I don't want to take that away from her," said Dwayne Moss, Grace's dad.

Fortunately, he discovered an article featuring someone at The University of Texas Health Science Center at Houston (UTHealth) who could provide Grace with a high-tech treatment option - her own stem cells.

But the road to that help would be a long one. Grace's ordeal began at a regular dental checkup in her hometown in June 2016, when her dentist noticed what looked like a cyst on her lower right jaw, and referred her to a surgeon in San Antonio.

"We couldn't get an appointment with him so we actually drove up to San Antonio and went to the hospital when he was doing rounds. We thought we were just going to see him and go home but we were admitted and the very next day they did a biopsy," Moss said.

The pathology results came back in August 2016. It wasn't a cyst on Grace's jaw but an ameloblastoma, a benign, but aggressive, localized tumor.

In October 2016, the tumor was removed, along with a third of her jaw bone, and a titanium bar and spacer were placed to support the mouth from the hinge to the jaw.

"The doctor removed the tumor with minimal margins, so he wanted to wait six months before performing her next surgery to make sure the tumor didn't return. The next surgery was supposed to be a bone graft taking Grace's fibula and using that to construct a new jaw," Moss said.

Those six months gave Moss the opportunity to see what other options existed for his daughter. He started researching and came across a journal article featuring James Melville, DDS, associate professor of oral and maxillofacial surgery at UTHealth School of Dentistry.

Moss reached out to Melville about a month before the scheduled bone graft surgery.

"When Dr. Melville responded to my email I was like, 'Oh wow, there's hope!'" Moss said.

Melville reconstructed Grace's jaw using tissue engineering. Stem cells from Grace's hip were placed in a centrifuge to concentrate them, and then combined with bone morphogenic protein and bone donated from another source to create a bone graft just like the one that would have come from her leg.

"It's regenerative medicine and the jaw bone Grace has now was completely regenerated from cells taken from within her own body. In my opinion, it's the next step in medicine," Melville said.

UTHealth is a pioneer in this type of procedure.

"We are one of only two institutions that perform this procedure and I have personally performed over 100 of them," Melville said, who added that several studies have been published about the procedure.

Three years later, Grace is now a healthy 12-year-old girl leading a normal, active life and is able to play softball, basketball, and volleyball, and run track and field. She wants to tell everyone her story with the hope that it can help someone else going through something similar.

"I want to be able to help people who don't know how to feel when they get a diagnosis like this. They might be scared, confused, and hopeless, but they aren't alone," Grace said.

Moss is incredibly proud of Grace for sharing her story. "Helping people is right up her alley," he said.

For Melville, it's all about the look Grace has on her face whenever she walks into his office.

"The best thing for me is that she got her smile back," he said.

View post:
Girl gets her smile back - and a new jaw - thanks to innovative tissue engineering procedure - Newswise

Bone Regeneration Material Market: Introduction

Bone-regeneration techniques, either with autografts or allografts, represent a challenge for reconstructive surgery. Biomaterials are temporary matrices for bone growth and provide a specific environment and architecture for tissue development. Depending on the specific intended application of the matrix, whether for structural support, drug-delivery capability, or both, certain material categories may be more or less well suited to the final structure.

Read Report Overview - https://www.transparencymarketresearch.com/bone-regeneration-material-market.html

Key Drivers and Restraints of Global Bone Regeneration Material Market

Increase in prevalence of degenerative joint diseases boost the market. Worldwide estimates of degenerative joint diseases indicate that 9.6% men and 18.0% women above 60 years have symptomatic osteoarthritis. According to expert opinions presented in the EULAR committee report, radiographic evidence of knee osteoarthritis in men and women over 65 years of age is found in 30% of the population.

In the absence of disease modifying therapy, a large number of patients with osteoarthritis progress to advance joint destruction. Surgery with bone grafts and substitutes play a major role in the management of osteoarthritis to avoid advanced joint destruction. According to the American College of Rheumatology, advances in biomaterial and tissue engineering are expected to create new opportunities to integrate surgical approaches in osteoarthritis.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=80488

Increase in the number of orthopedic surgeries also fuels the market. According to the American Academy of Orthopaedic Surgeons (AAOS), approximately 129,000 total knee arthroplasty (TKA) surgeries were performed in the U.S. in 1990, and the number has increased to over 600,000 in 2010. The AAOS has projected that 3 million TKA procedures would be performed by 2030 in the U.S. alone. Moreover, spinal surgeries are becoming increasingly popular, and approximately 432,000 spinal fusions are performed in the U.S. each year. Bone grafts and substitutes are extensively used for the surgeries mentioned above. This is likely to fuel the bone regeneration material market.

Bone graft and substitutes are a long-term solution to bone problem treatment; however, these are expensive. No two patients or their customized bone grafts and substitutes treatments are exactly alike. Hence, the number of appointments, procedures, and costs vary accordingly. Surgeons charge US$ 35,000 to US$ 40,000 for a complex posterolateral lumbar spine fusion bone graft surgery. Most surgeons refer patients to specialty surgeons, neurologists, or orthopedic physicians, which increases the cost of procedure. Asia is price-sensitive and displays inhibitions with respect to investing in bone graft and substitutes, which are often only affordable to the elite population; therefore offering a comparatively smaller market.

Request for Analysis of COVID-19 Impact on Bone Regeneration Material Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=80488

Cell-based Segment to Expand Significantly

Based on product type, the global bone regeneration material market can be divided into ceramic-based, polymer-based, growth factor-based, cell-based and others

The ceramic-based segment dominated the global market in 2019. It is projected to sustain its position during the forecast period. Ceramic-based bone grafts are widely used to reduce the need for iliac crest bone grafting. Rise in geriatric population with oral health issues across the world has augmented the number of bone graft surgeries performed in the last few years.

However, the cell based segment is projected to expand at a notable CAGR during the forecast period. Bone tissue engineering (BTE) using bone marrow stem cells has been suggested as a promising technique for reconstructing bone defect in order to overcome the drawbacks of bone graft materials.

Orthopedic surgery segment to dominate global bone regeneration material market

Based on application, the global bone regeneration material market can be segregated into orthopedic surgery, bone trauma, dental surgery and others.

In terms of revenue, the orthopedic surgery segment accounted for a prominent share of the market in 2019 owing to a rise in the geriatric population and increase in cases of orthopedic diseases. According to WHO, between 2015 and 2050, the proportion of the world's population over 60 years would nearly double from 12% to 22%. The number of people aged 60 years and older is estimated to outnumber children younger than 5 years by 2020. As per MVZ Gelenk-Klinik data, more than 2400 orthopedic surgical procedures are performed per year at the Gelenk Klinik Orthopaedic Hospital.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=80488

North America to dominate global bone regeneration material market

In terms of region, the global bone regeneration material market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

North America accounted for a significant share of the bone regeneration material market in 2019, followed by Europe. Usage of new and innovative products in both premium and value segments among various bone grafts substitutes is projected to boost the bone regeneration material market in several countries in Europe and North America in the next few years. According to the Centers for Disease Control and Prevention (CDC), the total number of inpatient surgeries carried out in the U.S. were 51.4 million in 2014; of these 719,000 were total knee replacements and 332,000 were total hip replacement.

The market in developing countries in Asia Pacific is estimated to expand at a significant CAGR during the forecast period. The market in Asia Pacific is driven by an increase in population and time taken to accept new technologies. Increase in the number of patients and geriatric population are major factors that are expected to propel the market in Japan during the forecast period. According to the Gerontological Society of America, Japan has the highest proportion of geriatric population in the world. Hence, demand for orthopedic surgeries is estimated to be higher in Japan than that in other countries in Asia Pacific.

Pre Book Bone Regeneration Material Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=80488&ltype=S

Key Manufacturers Operating in Market

The global bone regeneration material market was highly fragmented in 2019. Key manufacturers operating in the global market are:

Browse More Trending Reports by Transparency Market Research:

Tactile Imaging Market: https://www.transparencymarketresearch.com/tactile-imaging-market.html

Eye Stent Market: https://www.transparencymarketresearch.com/eye-stent-market.html

Podiatry Workstations Market: https://www.transparencymarketresearch.com/podiatry-workstations-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

See more here:
Bone Regeneration Material Market: Cell-based Segment to Expand Significantly - BioSpace

In this world nothing can be said to be certain, except death and taxes, as Benjamin Franklin remarked. But just as tax rates differ depending on the jurisdiction, so life expectancy varies across borders.

As the chart below shows, there are big gaps in longevity even between the relatively affluent countries of Europe, where a Spanish woman can expect to live more than 16 years longer than a Latvian man.

Life expectancy varies greatly access Europe's different economies.

Image: OECD

So what makes some countries more conducive to a long life than others?

What people eat is a major factor. Long life is more common in places where the Mediterranean diet is the norm, such as Spain, Italy and Cyprus. Numerous scientific studies have proved the benefits of the typical Mediterranean diet: high in vegetables, fruits, nuts, olive oil and fish, and low in meat (especially red meat) and most dairy products. The combination reduces the risk of strokes and heart attacks, the two biggest killers worldwide. At the other end of the scale, there is a much higher incidence of heart and circulatory diseases in Eastern Europe, the Balkans and the Baltic states.

Health spending also plays a significant role. Switzerland and the Scandinavian countries spend three or four times the amount of money per capita on healthcare than the average in Eastern Europe. This mirrors the situation in the rest of the world, where there is a strong correlation between health and wealth.

Each year, $3.2 trillion is spent on global healthcare making little or no impact on good health outcomes.

To address this issue, the World Economic Forum created the Global Coalition for Value in Healthcare to accelerate value-based health systems transformation.

This council partners with governments, leading companies, academia, and experts from around the world to co-design and pilot innovative new approaches to person-centered healthcare.

Other factors that can affect longevity include lifestyle choices such as alcohol consumption and smoking, environmental issues like air pollution, and genetics. In every country, women tend to live significantly longer than men, with the biggest gaps in the Baltic states, and the smallest in the Netherlands.

A long life doesnt necessarily mean a healthy old age, as the chart below demonstrates.

Life expectancy and healthy life years at birth, by gender, 2018 (or nearest year)

Women are expected to live longe than men.

Image: OECD

For example, both men and women in Bulgaria are healthy and active for longer than in Portugal, even though their overall life expectancy is less. As more nations have ageing populations, getting more out of later life is becoming an increasingly important challenge.

Alzheimers Diesease, a result of rapid ageing that causes dementia, is a growing concern. Dementia, the seventh leading cause of death worldwide, cost the world $1.25 trillion in 2018, and affected about 50 million people in 2019. Without major breakthroughs, the number of people affected will triple by 2050, to 152 million.

To catalyse the fight against Alzheimer's, the World Economic Forum is partnering with the Global CEO Initiative (CEOi) to form a coalition of public and private stakeholders including pharmaceutical manufacturers, biotech companies, governments, international organizations, foundations and research agencies.

The initiative aims to advance pre-clinical research to advance the understanding of the disease, attract more capital by lowering the risks to investment in biomarkers, develop standing clinical trial platforms, and advance healthcare system readiness in the fields of detection, diagnosis, infrastructure and access.

There is a caveat to the data in the OECD report: it all predates the COVID-19 pandemic. Until 2018, life expectancy had been increasing across the EU, although more slowly in recent years. It is possible that in the worst-hit countries, among them Spain and Italy, 2020 could see a decline in life expectancy for the first time in decades.

Go here to read the rest:
Which countries have the highest life expectancy in Europe? - World Economic Forum

Monday, 14 December 2020, 2:58 pmPress Release: Ministry For Primary Industries

New research backed by the Ministry for PrimaryIndustries (MPI) could help bumblebee hives to live longerand be more efficient.

The new project is researchingways to protect the long-term sustainability of New Zealandhorticulture, including how to enhance the performance ofbumblebee hives using pheromones.

MPI is contributing$160,000 towards the $400,000 project through itsSustainable Food & Fibre Futures (SFF Futures)fund.

Dr Gunjan Gera of Gourmet Waiuku Limited isleading the project, supported by consultant Dr JoStephens.

Dr Gera says bumblebees are often used forpollination in berryfruit crops, glasshouses, and othercovered crop areas as the bees tend to travel only about 200metres from their hives and dont mind enclosed spaces,whereas honeybees prefer to fly to flowers furtherafield.

In the field, the queen bumblebee of acommercial hive lives for approximately 8-10 weeks and thehive winds down once the queen dies, says DrGera.

With fewer worker bees, the hives can appearless active when compared to honeybees and there can bevariation in vigour and productiveness.

Our projectwill study various factors and compounds in conjugation withthe bumblebee queens to see if we can extend the life of ahive to at least 12-18 weeks. If this works, we have a wayof complementing nature, using a pheromonesubstitute.

The technology is in its infancyoverseas and commercial companies using it havent yetreleased much information, says Dr JoStephens.

Were hoping to lead the way in NZ, butit will involve a good deal of trial and error given thelimited progress globally in this area.

Dr Stephensexplains that bumblebees were introduced to New Zealand fromthe United Kingdom by the early pioneers, so there islimited genetic diversity. Although commercial breedersincorporate new genetic diversity from the wildoccasionally, the gene pool is limited.

Anotherimportant part of the research will be screening bumblebeesfor diseases, including those associated withinbreeding.

Well be looking at the levels ofinbreeding in New Zealand populations to see if this is amajor concern, and whether we need to consider thepossibility of importing bumblebee genetics.

MPIInvestment Programmes director Steve Penno says this projectcould help increase the productivity of bumblebee hivesdramatically.

Enhancing bumblebee activity wouldmean better pollination for growers, which means higheryields and better quality produce, he says.

As wellas the bumblebee research, the project will also look atdeveloping technology to rear Limonicuspredatory mites. Thismite is effective in controlling thrips, whiteflies, andother mites in greenhouses and protected culture systems.While it occurs naturally in New Zealand, it is currentlyonly reared overseas and is re-imported for New Zealandgrowers.

This is expensive, time-consuming, andtheres always the risk of supply shortages, says DrGera.

If we can successfully rear these mites forcommercial production and release them in New Zealand itwill be far more cost-effective to controlpests.

Scoop Media

Become a member Find out more

Read more:
New Research Aims To Increase Longevity Of Bumblebee Hives For NZ Growers - Scoop.co.nz

Twenty years ago, President Bill Clinton announced completion of what was arguably one of the greatest advances of the modern era: the first draft sequence of the human genome.

"Without a doubt, this is the most important, the most wondrous map ever produced by humankind," Clinton said on June 26, 2000 from the White House, predicting that genome science "will revolutionize the diagnosis, prevention and treatment of most, if not all, human diseases." In the future, he said, "doctors will increasingly be able to cure diseases like Alzheimer's, Parkinson's, diabetes, and cancer by attacking their genetic roots."

And indeed, the sequencing of the human genome achieved simultaneously by the Human Genome Project (HGP), an international consortium begun in 1990 and led by Francis Collins, MD, then director of the National Human Genome Research Institute, and by J. Craig Venter, PhD, with his team at the privately held Celera Genomics has revolutionized the approach to human health.

President Bill Clinton is flanked by Dr J. Craig Venter (left) and Dr Francis Collins announcing the first draft sequence of the human genome in June 2000.

Although the unbridled optimism of 20 years ago has not been matched with success in every quarter, much of the promise has begun to be realized. Scientists have so far identified 5000 rare diseases and 40 to 50 genes that confer cancer risk, developed simple prenatal blood tests to detect chromosomal abnormalities, and generated genetic profiles of tumors to facilitate better-targeted therapies, among other accomplishments. Even the current global fight against COVID-19 is relying on genomics.

"There hasn't been a pharmaceutical developed in last 20 years that hasn't utilized genome information," Venter told Medscape Medical News.

"Not a day goes by in science that we don't see some offshoot of benefit from what happened 20 years ago," said Eric Topol, MD, the chair of innovative medicine at Scripps Research in La Jolla, California, and Editor-in-Chief of Medscape.

Finding the genes was just the beginning though; describing function and using that information therapeutically is still just getting underway in many clinical areas. "We now know that genes are only a small fraction of the complexity of the human genome," says Eric Green, MD, PhD, the current director of the National Human Genome Research Institute (NHGRI).

When it started, the sequencing of the human genome did not seem like a value proposition nor was it expected to be. Congress authorized $3 billion for the HGP in 1990 and set a target completion date of 2005.

The final sequence, a database of some 3 billion DNA base pairs, came in under budget the NHGRI estimates the cost at $2.7 billion in 2003, two years ahead of schedule and exactly 50 years after James Watson and Francis Crick first described DNA.

It had been only 15 months since the international consortium of 1000 researchers across six nations began their sequencing effort in earnest, and a scant 9 months from when Venter's team starting sequencing its human genome. Celera Genomics spent just $100 million, Venter estimates.

What seemed like a massive investment at the time now looks like chicken scratch. "It was a bargain," Topol said.

The race to create the map of the human genome would generate goodwill, create strife, elevate egos, and make careers. Much has been written about the clash between Collins and Venter two polar opposites with different motivations and different approaches.

Collins, a dedicated public servant and man of deep Christian faith, believed in the power of the academic and governmental research enterprise.

Venter, on the other hand, ruffled feathers with his big ideas and generally more capitalistic approach. He began his career at the National Institutes of Health (NIH) in 1984 and created a gene discovery tool called expressed sequence tags (ESTs). That caught the eye of venture capitalists, who lured him out of the agency. They backed Venter's nonprofit, The Institute for Genomic Research (TIGR), to develop the technology.

At TIGR, Venter decoded the genome of Haemophilus influenzae using his whole genome "shotgun" technique. When he applied to the NIH for a grant to support the shotgun method, however, he was rejected. The maker of a DNA sequencing machine, PE Biosystems, then installed Venter as the CEO of the new, private Celera Genomics in 1998.

The NIH-led consortium did not see the value of the shotgun approach and instead relied on a more traditional sequencing method, which was more laborious and time-consuming, Topol recalls. After that NIH rejection, the competition was on, and the rivalry became bitter.

"There was no love lost between these two gentleman," Topol acknowledged. On that day in June 2000 when the announcement was made, "it required Clinton and whoever else to kind of get them to stand together and make nice," added Topol, who was present at the celebration.

A release from the NIH on the commemoration of the 20th anniversary in June of this year describes the situation this way: "The joint presence of these two scientific leaders signified the agreed-upon shared success of the public HGP and private Celera Genomics efforts in generating the first draft sequence of the human genome."

Still, the competition, in retrospect, was a good thing because it accelerated progress, Topol said.

The draft sequence unveiled in 2000 covered 90% of the genome at an error rate of one in 1000 base pairs, but there were more than 150,000 gaps, and only 28% of the genome had reached true completion. When the final version was made public in 2003, there were less than 400 gaps and 99% of the genome was finished with an accuracy rate of less than one error in every 10,000 base pairs.

Looking back, the technologies used then "now seem almost prehistoric," says NHGRI director Green. "Nothing in the way we sequence DNA is the same now. We can do it in a day or two and it costs less than a thousand dollars." He expects the cost of sequencing a human genome will eventually drop below $100.

The final, almost-complete sequence published in 2003 was "foundational," providing "the alphabet around which everything else has been constructed," said Mark McCarthy, MD, senior director and staff scientist in human genetics at the California-based biotechnology company, Genentech. "It's hard to think of a more concrete example in science other than maybe the periodic table," McCarthy told Medscape Medical News.

Doing genetic research before the full sequence was published, he says, was like being an "explorer in some novel land." Without a clear map of the terrain, researchers used analogue methods to try to determine locations of genes or recombination events, he said. It was frustrating and "a huge impediment to progress."

Now, scientists can "just click on a mouse and get almost immediately the worlds of data around any genomic regions," he said.

"Most scientists today never had to sequence a gene," Venter points out. "They don't have to, because they just look it up on the internet."

"Graduate students today can't imagine how we ever did any experiments or learned anything without having access to the human genome sequence with a click of a mouse," said Collins, in a video testimonial celebrating the 30th anniversary of the start of the project.

To Collins, one of the genome project's main goals was to give clinicians better tools to heal their patients. "Together we must develop the advances in medicine, that is the real reason for doing this work," he said in 2000.

If you would have told me that in my professional career I would have seen genomics actually change the practice of medicine in any way, shape, or form, I would have said, 'There's just no way, we're two generations away from that.' Dr Eric Green, director of the National Human Genome Research Institute

But it wasn't until a decade later that genomics was talked about in medicine, said Green. "Now, we have clear examples for genomics being used every day," he said.

"If you would have told me that in my professional career I would have seen genomics actually change the practice of medicine in any way, shape or form, I would have said, 'There's just no way, we're two generations away from that,'" Green said.

Perhaps the biggest impact of these advances in genomics to date has been in the practice of oncology.

"Cancer care has been one of the biggest beneficiaries of the genomic revolution," said Frederick M. Schnell, MD, chief medical officer of the Community Oncology Alliance (COA). Schnell points to the work of Brian Druker, MD, who helped discover the mutation that causes chronic myelogenous leukemia and also was instrumental in developing a precision treatment for CML, imatinib (Gleevec).

"That was probably the singular most important development for a particular, albeit not common, but not uncommon disease that had a disgraceful, horrible projected survival and mortality associated with it, and has changed it to a curable disease," Schnell told Medscape.

The HGP led to the Cancer Genome Atlas, a book of some 20,000 cancer genomes and matched normal samples spanning 33 cancer types.

"In order to understand what was going wrong in a cancer, you first had to understand what the genome was supposed to look like in somebody the cell that was not cancerous," said Richard Schilsky, MD, chief medical officer and executive vice president of the American Society of Clinical Oncology (ASCO).

The comparisons "help us identify mutations that are real drivers of cancer and have opened up the whole field of precision oncology," Schilsky, formerly chief of hematology/oncology and deputy director of the University of Chicago Comprehensive Cancer Center, told Medscape Medical News.

In addition to helping identify cancer susceptibility genes, the genome project also led to variations associated with how drugs are metabolized, Schilsky said.

For instance, it is now known that 10% of the population has a variant of the UGT1A1 gene that leads to poor metabolism of the chemotherapy drug irinotecan (Camptosar), causing worse side effects. The drug's label now notes the availability of a simple lab test to look for the variant.

Schilsky is lead investigator of an ASCO-sponsored trial called TAPUR that aims to match patients with certain tumor variants to therapies that might work, but are not FDA-approved for that particular cancer. Some 2000 individuals have enrolled and received free medications (provided by one of the eight drug companies participating) since the trial began in 2016, said Schilsky.

One goal is to collect evidence on off-label uses which might help therapies gain acceptance in clinical practice guidelines and, potentially, reimbursement. TAPUR also aims to help oncologists learn more about genomics.

Precision oncology is still not available to all cancer patients, however. Schnell said the COA is lobbying for better access and insurance coverage.

He believes that genomics could be used as a replacement for screening tests such as mammograms and colonoscopies. "This is going to be a big application point for the genomic revolution as it continues," he said.

Topol agrees that genomics could create a tailored approach to prevention. "Why does every woman need a mammogram when only 12% will ever develop breast cancer?" he says.

The progress made to date in understanding the human genome is also proving to be a key weapon as scientists fight the important current threat of the COVID-19 pandemic.

China made the first genetic sequence of the SARS-CoV-2 virus available on January 12, 2020, just weeks after the nation reported the initial cluster of cases.

Researchers have since uploaded 245,000 genomic sequences of the SARS-CoV-2 virus to the World Health Organization's Global Initiative on Sharing All Influenza Data (GISAID) portal. The speedy sequencing and widespread sharing of data led to quick development of molecular diagnostics and identification of potential targets for vaccines and therapeutics.

The NHGRI, among others, is supporting genomic studies around the world that aim to understand the differences between those who become severely ill and those "who barely seem to notice they have the disease," NHGRI director Green told Medscape Medical News. "There is no question there is going to be some genomic basis for the severity of the disease,"

He also expects genomics to be used in vaccine trials to separate responders from nonresponders.

While rare monogenic diseases were a relative cinch, common illnesses like hypertension, diabetes, and Alzheimer's disease have turned out to be more complicated.

It wasn't until the mid-2000s, when genome-wide association studies (which look for small variations that occur more frequently in people with disease) came into greater use, that scientists began to get a clearer picture, said Genentech's McCarthy.

It turns out that "hundreds, if not thousands of genetic variations and genetic regions" seem to predispose someone to a common disease, he said. He's applying genome-wide approaches in type 2 diabetes, but it requires datasets of a million or more people to get a robust result, McCarthy said.

Even then, "it just gives you a bunch of sign posts around the genome and then you have to work out what they do and how they influence predisposition in a given individual," he said. Researchers have begun to understand "the range of pathways and networks that are involved in the genetic predisposition to type 2 diabetes," which in turn is giving information on potential therapeutic targets.

The obstacle is not having enough genome-wide genetic data, which may change as more countries find ways to collect more genetic data, McCarthy said.

"We're not getting complete comprehensive views of all the genes involved and all the genomic variants that confer risk," for chronic diseases, agreed Green. "That's the big challenge for the next decade."

Another challenge that NHGRI has outlined in its strategic plan, released in October, is broadening human genome reference databases to include a wider representation of humanity. "Much like all other scientific disciplines, genomics is reckoning with systematic injustice and biases of the past," the agency said in a press release. The plan also addresses data control, privacy, genome editing, and barriers to a thriving genomics enterprise.

Venter believes that getting to the root of chronic diseases means combining the phenotype with the genotype. In 2013, he started Human Longevity, a company that offers sequencing, imaging, and a host of diagnostics to those who can afford the service, to give a complete picture.

"Without extensive phenotype information, the genome isn't highly useful on its own," said Venter, who feels the combination could be a true preventive medicine platform.

As much as the sequencing of the genome has brought to medicine, "I think the greatest promise of the genome remains to be realized," said Venter.

The initial focus was on genes. Humans, it turns out, have only 20,000 genes, not that many more than worms or fruit flies. But there's more to life outside of those genes, said Green.

The human genome "is a treasure chest, but we have only gotten a limited number of the keys so far," said Topol. "It is not nearly as informative as it could be."

And genomics still has the potential to do harm an issue that gets periodic scrutiny by commissions and the public. On that day in 2000 at the White House, Venter noted that a just-released poll had reported that 46% of Americans believed that "the impact of the Human Genome Project will be negative."

Privacy of genetic information is a perennial concern, and technologies such as gene editing, which allows scientists to alter DNA have brought up new ethical challenges.

On the other hand, the public has been mesmerized by genetic genealogy technologies that allow them to determine their own ancestry or disease risk, and that have more recently helped law enforcement solve crimes, some of them longstanding cold cases.

Twenty years ago, Venter predicted that the wonders would continue unabated. "The complexities and wonder of how the inanimate chemicals that are our genetic code give rise to the imponderables of the human spirit should keep poets and philosophers inspired for the millenniums," he said in 2000.

His view is more tempered today. "I'm optimistic about the future," says Venter now. "I'm pessimistic about how soon it will get here."

For more Medscape Neurology news, join us on Facebook and Twitter

Original post:
The 'Wondrous Map': Charting of the Human Genome, 20 Years Later - Medscape

In October of 1992, genetics researchers made a potentially groundbreaking discovery.

Their findings were published in Nature, and stated that a genetic variant in the angiotensin-converting enzyme ACE appeared to alter an individuals risk of having a heart attack.

The study involved a total of over 500 individuals from four categories.

After publication of these results, there was initial excitement because this same polymorphism was associated with diabetes and longevity, but after inconclusive replication studies, this excitement swiftly transitioned into disappointment.

In 2000, 8 years after the initial report, a large study involving over 5,000 cases and controls found no detectable effect of the ACE polymorphism on an individual's risk of heart attack.

Meanwhile, the same polymorphism had been detected in dozens of other association studies linking it to a wide range of genetic traits ranging from obstetric cholestasis to meningococcal disease in children.

Its not rare for initial reports of associations between candidate genes and complex diseases to fail to replicate when further studies are conducted.

Common genetic polymorphisms have an insignificant impact on the risk of disease and sample sizes are often too small to prove anything.

Detecting these subtle effects requires studies involving not just dozens or hundreds of individuals, but thousands or tens-of-thousands.

In small studies, investigators often look at only one or at most, a few variants in a single gene. They then subset the data (splitting males and females, for example) to find significant results in a specific subgroup.

However, this, combined with a tendency to be biased towards positive results rather than highlighting negative results also, results in a conflicted and confusing body of literature which has ultimately slowed down progress in this area of research.

More recently, the medical genetics community has identified thousands of associations between genetic variants and disease that can be proven consistently and robustly.

This is down to innovations in genome-wide association studies carried out on thousands of individuals.

Not only can these studies detect tiny effects, but theyre not constrained to a particular starting hypothesis regarding specific parts of the genome being associated with a particular disease.

Despite this progress, researchers continue to make this two-decade-old mistake even today. This can be seen in the paper in question by Alex Kogan and colleagues.

This study looked at the candidate gene (the oxytocin receptor) and tested for association between a genetic variant in this gene and a trait called prosociality in a sample of 23 individuals.

If the effect sizes of genetic variants on relatively well-defined traits like diabetes and heart attack are small, the effect sizes of genetic variants on less well-defined traits like prosociality must be even smaller.

Link:
Size Matters, And Other Lessons From Medical Genetics - Genomes Unzipped